• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

与甲状腺癌相关的肿瘤抑制基因甲基化。

Methylation of tumour suppressor genes associated with thyroid cancer.

机构信息

'Stefan S. Nicolau' Institute of Virology, Bucharest, Romania.

'CI Parhon' National Institute of Endocrinology, Bucharest, Romania.

出版信息

Cancer Biomark. 2019;25(1):53-65. doi: 10.3233/CBM-182265.

DOI:10.3233/CBM-182265
PMID:31006665
Abstract

BACKGROUND

Thyroid carcinoma is the most common endocrine malignancy worldwide. Changes in DNA methylation can cause silencing of normally active genes, especially tumour suppressor genes (TSG) or activation of normally silent genes.

OBJECTIVE

The aim of this study is to evaluate the degree of promoter methylation for a panel of markers for thyroid neoplasms and to establish their relationship with thyroid oncogenesis.

METHODS

To generate a comprehensive DNA methylation signature of TSGs involved in thyroid neoplasia, we use Human TSG EpiTect Methyl II Signature PCR Array-Qiagen for 24 samples (follicular adenomas and papillary thyroid carcinomas) compared with normal thyroid tissue. We extended the evaluation for three TSGs (TP73, WIF1, PDLIM4) using qMS-PCR. Statistical analysis was performed with GraphPad Prism.

RESULTS

We noted four important genes NEUROG1, ESR1, RUNX3, MLH1, which presented methylated promoter in tumour samples compared to normal. We found new characteristic of thyroid tumours: methylation of TP73, WIF1 and PDLIM4 TSGs, which can contribute to thyroid neoplasia. A significant correlation between BRAF V600E mutation and RET/PTC rearrangements with TIMP3 and CDH13, RARB methylation, respectively was observed.

CONCLUSIONS

TSGs promoter hypermethylation is a hallmark of cancer and a test that uses methylation quantification method is suitable for diagnosis and prognosis of thyroid cancer.

摘要

背景

甲状腺癌是全球最常见的内分泌恶性肿瘤。DNA 甲基化的改变可导致正常活跃基因沉默,尤其是肿瘤抑制基因(TSG)或正常沉默基因的激活。

目的

本研究旨在评估甲状腺肿瘤标志物的启动子甲基化程度,并确定其与甲状腺癌发生的关系。

方法

为了生成甲状腺肿瘤中涉及的 TSG 的综合 DNA 甲基化特征,我们使用 Human TSG EpiTect Methyl II Signature PCR Array-Qiagen 对 24 个样本(滤泡性腺瘤和甲状腺乳头状癌)与正常甲状腺组织进行比较。我们使用 qMS-PCR 扩展了对三个 TSG(TP73、WIF1、PDLIM4)的评估。使用 GraphPad Prism 进行统计分析。

结果

我们注意到四个重要的基因 NEUROG1、ESR1、RUNX3、MLH1,其启动子在肿瘤样本中与正常样本相比发生了甲基化。我们发现了甲状腺肿瘤的新特征:TP73、WIF1 和 PDLIM4 TSG 的甲基化,这可能有助于甲状腺肿瘤的发生。BRAF V600E 突变和 RET/PTC 重排与 TIMP3 和 CDH13、RARB 甲基化之间分别存在显著相关性。

结论

TSG 启动子的高甲基化是癌症的一个标志,使用甲基化定量方法的检测适合甲状腺癌的诊断和预后。

相似文献

1
Methylation of tumour suppressor genes associated with thyroid cancer.与甲状腺癌相关的肿瘤抑制基因甲基化。
Cancer Biomark. 2019;25(1):53-65. doi: 10.3233/CBM-182265.
2
Alterations of regulatory factors and DNA methylation pattern in thyroid cancer.甲状腺癌中调控因子和 DNA 甲基化模式的改变。
Cancer Biomark. 2020;28(2):255-268. doi: 10.3233/CBM-190871.
3
Identification of tumour-specific epigenetic events in medulloblastoma development by hypermethylation profiling.通过高甲基化分析鉴定髓母细胞瘤发生过程中的肿瘤特异性表观遗传事件
Carcinogenesis. 2004 May;25(5):661-8. doi: 10.1093/carcin/bgh055. Epub 2003 Dec 19.
4
DKK3 is a potential tumor suppressor gene in papillary thyroid carcinoma.DKK3 是甲状腺乳头状癌中一种潜在的肿瘤抑制基因。
Endocr Relat Cancer. 2013 Jun 27;20(4):507-14. doi: 10.1530/ERC-13-0053. Print 2013 Aug.
5
Epigenetic signatures of familial cancer are characteristic of tumor type and family category.家族性癌症的表观遗传特征是肿瘤类型和家族类别的特征。
Cancer Res. 2008 Jun 15;68(12):4597-605. doi: 10.1158/0008-5472.CAN-07-6645.
6
Hypermethylation of RUNX3 but not WIF1 gene and its association with stage and nodal status of tongue cancers.RUNX3 基因高甲基化而非 WIF1 基因,且与舌癌的分期和淋巴结状态相关。
Oral Dis. 2011 Nov;17(8):794-800. doi: 10.1111/j.1601-0825.2011.01838.x. Epub 2011 Aug 8.
7
Silencing of the maspin gene by promoter hypermethylation in thyroid cancer.甲状腺癌中maspin基因因启动子高甲基化而沉默。
Int J Mol Med. 2003 Oct;12(4):479-84.
8
Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer.甲状腺乳头状癌中肿瘤抑制基因异常甲基化与肿瘤侵袭性及BRAF突变的相关性
Int J Cancer. 2006 Nov 15;119(10):2322-9. doi: 10.1002/ijc.22110.
9
Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAF(V600E): A non-invasive tool panel for early detection of thyroid cancer.循环游离 DNA、SLC5A8 和 SLC26A4 高甲基化、BRAF(V600E):甲状腺癌早期检测的非侵入性工具面板。
Biomed Pharmacother. 2013 Oct;67(8):723-30. doi: 10.1016/j.biopha.2013.06.007. Epub 2013 Jul 5.
10
[Aberrant methylation of hMLH1 gene promoter in papillary thyroid cancer and its clinical significance].甲状腺乳头状癌中hMLH1基因启动子的异常甲基化及其临床意义
Zhonghua Zhong Liu Za Zhi. 2013 Nov;35(11):833-6.

引用本文的文献

1
Deciphering the role of Hashimoto's Thyroiditis-related key genes in thyroid cancer via detailed in silico analysis followed by the experimental validation.通过详细的计算机模拟分析,随后进行实验验证,来阐明桥本甲状腺炎相关关键基因在甲状腺癌中的作用。
Hereditas. 2025 May 31;162(1):91. doi: 10.1186/s41065-025-00429-0.
2
Hybrid Albumin-Decorated Lipid-Nanocarrier-Mediated Delivery of Polyphenol-Rich L. in a Potential Multiple Antitumoural Therapy.基于载多酚丰富 L 的杂化白蛋白修饰的脂质纳米载体介导的给药系统在潜在的多肿瘤治疗中的应用。
Int J Mol Sci. 2024 Oct 18;25(20):11206. doi: 10.3390/ijms252011206.
3
PCDH1, a poor prognostic biomarker and potential target for pancreatic adenocarcinoma metastatic therapy.
PCDH1,一种预后不良的生物标志物,也是胰腺导管腺癌转移治疗的潜在靶点。
BMC Cancer. 2023 Nov 13;23(1):1102. doi: 10.1186/s12885-023-11474-1.
4
Identification and Validation of a Prognostic Signature Based on Methylation Profiles and Methylation-Driven Gene as a Prognostic Biomarker in Differentiated Thyroid Carcinoma.基于甲基化谱和甲基化驱动基因的鉴别和验证分化型甲状腺癌的预后标志物
Dis Markers. 2022 Sep 17;2022:1686316. doi: 10.1155/2022/1686316. eCollection 2022.
5
Novel Bovine Serum Albumin-Decorated-Nanostructured Lipid Carriers Able to Modulate Apoptosis and Cell-Cycle Response in Ovarian, Breast, and Colon Tumoral Cells.新型牛血清白蛋白修饰的纳米结构脂质载体能够调节卵巢、乳腺和结肠肿瘤细胞中的细胞凋亡和细胞周期反应。
Pharmaceutics. 2023 Apr 2;15(4):1125. doi: 10.3390/pharmaceutics15041125.
6
Transcriptomic landscape of TIMP3 oncosuppressor activity in thyroid carcinoma.甲状腺癌中TIMP3抑癌活性的转录组图谱
Cancer Cell Int. 2022 Dec 12;22(1):400. doi: 10.1186/s12935-022-02811-8.
7
Promoter Methylation of Tumor Suppressors in Thyroid Carcinoma: A Systematic Review.甲状腺癌中肿瘤抑制基因的启动子甲基化:一项系统评价
Iran J Public Health. 2021 Dec;50(12):2461-2472. doi: 10.18502/ijph.v50i12.7928.
8
VHL tumor suppressor as a novel potential candidate biomarker in papillary thyroid carcinoma.VHL 肿瘤抑制因子作为甲状腺乳头状癌的一种新型潜在候选生物标志物。
Biomol Biomed. 2023 Feb 1;23(1):26-36. doi: 10.17305/bjbms.2022.7850.
9
Epigenetic Regulation: A Link between Inflammation and Carcinogenesis.表观遗传调控:炎症与致癌作用之间的联系
Cancers (Basel). 2022 Feb 26;14(5):1221. doi: 10.3390/cancers14051221.
10
Epigenetic modification and BRAF gene mutation in thyroid carcinoma.甲状腺癌中的表观遗传修饰与BRAF基因突变
Cancer Cell Int. 2021 Dec 19;21(1):687. doi: 10.1186/s12935-021-02405-w.